Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (42)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hemminki, K.
Right arrow Articles by Hansson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemminki, K.
Right arrow Articles by Hansson, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 18, 9-13, Copyright © 1997 by Oxford University Press


ARTICLES

Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients

K Hemminki, H Rajaniemi, M Koskinen and J Hansson
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden.

Tamoxifen-induced DNA adducts were searched in leucocyte DNA from breast cancer patients. Total white blood cell DNA from tamoxifen- treated and control patients was analysed by 32P-postlabelling using HPLC-radioactivity detection. Rat liver DNA was used as a positive standard. In blinded analysis four of the six treated patients showed DNA adducts; none of the five controls were positive. The identity of fraction as a tamoxifen adduct was confirmed by using different chromatographic systems, each with spiked rat liver samples. The level of adducts in the treated patients was 5.5 adducts/10(9) nucleotides as compared to an apparent level of 1.9/10(9) in the controls.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
MutagenesisHome page
K. Brown
Is tamoxifen a genotoxic carcinogen in women?
Mutagenesis, September 1, 2009; 24(5): 391 - 404.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier
Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days
Cancer Res., September 15, 2003; 63(18): 5999 - 6003.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier
Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen
Cancer Res., August 1, 2003; 63(15): 4402 - 4406.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
M. C. Poirier and L. J. Schild
The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003
Mutagenesis, July 1, 2003; 18(4): 395 - 399.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Carcinogenesis, April 1, 2000; 21(4): 845 - 847.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Divi, M. R. Osborne, A. Hewer, D. H. Phillips, and M. C. Poirier
Tamoxifen-DNA Adduct Formation in Rat Liver Determined by Immunoassay and 32P-Postlabeling
Cancer Res., October 1, 1999; 59(19): 4829 - 4833.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. A. Beland, L. P. McDaniel, and M. M. Marques
Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo
Carcinogenesis, March 1, 1999; 20(3): 471 - 477.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Rajaniemi, I. Rasanen, P. Koivisto, K. Peltonen, and K. Hemminki
Identification of the major tamoxifen–DNA adducts in rat liver by mass spectroscopy
Carcinogenesis, February 1, 1999; 20(2): 305 - 309.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.